Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
175 hedge funds and large institutions have $4B invested in Blueprint Medicines in 2018 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 55 increasing their positions, 63 reducing their positions, and 24 closing their positions.
29% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 24
24% more capital invested
Capital invested by funds: $3.23B → $4B (+$771M)
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
3% more funds holding
Funds holding: 170 → 175 (+5)
1% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $16.3M
0.15% more ownership
Funds ownership: 99.69% → 99.84% (+0.15%)
13% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$30.2M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$25.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$17.9M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$15.9M |
| 5 |
BlackRock
New York
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
-$23.2M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$16.4M |
| 3 |
Morgan Stanley
New York
|
-$13.5M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$11.6M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$9.63M |
BPMC Hedge Fund Activity: Q1 2018 in Review
175 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2018, worth a combined $4B — up 24% from $3.23B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new BPMC positions and 24 closed out — a net gain of 7 holders — while 55 added to existing stakes and 63 trimmed.
The largest buyer was Artal Group, adding an estimated $30.2M. The largest seller was TimesSquare Capital Management, cutting an estimated $23.2M.
- 175 institutional investors held Blueprint Medicines (BPMC) as of Q1 2018, up from 170 in Q4 2017.
- Funds reported $4B of Blueprint Medicines stock for Q1 2018, up 24% quarter-over-quarter.
- 31 funds opened new Blueprint Medicines positions in Q1 2018 and 24 closed out, a net change of +7 holders.
- The largest Blueprint Medicines buyer in Q1 2018 was Artal Group, an estimated $30.2M added.
- The largest Blueprint Medicines seller in Q1 2018 was TimesSquare Capital Management, an estimated $23.2M sold.
Based on aggregated 13F filings for Q1 2018.